

#24
LB
9/24/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

WAGNER ET AL.

Examiner: Di Nola Baron, L.

APPLICATION NO: Not Yet Assigned

FILED: Herewith

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Kindly enter the following preliminary amendment prior to calculating the filing fee for the application.

IN THE SPECIFICATION

On page 1, after the title and before the first paragraph of the specification, please insert:

-- This application is a continuation of U.S. Application 09/202,805, filed May 7, 1999, which is a 371 of International Application PCT/EP97/03172, filed June 18, 1997. --

Please replace the first line of text (title) on page 1, with the following:

-- SOLID ORAL DOSAGE FORMS OF VALSARTAN --

Please replace the third paragraph on page 6, with the following rewritten paragraph:

-- Thus, where accelerated release is desired, e.g. about 90% release within a ten minute, more particularly a five minute period, a disintegrant such as crosslinked polyvinyl pyrrolidone, for example those products known under the registered trade marks Polyplasdone®XL or Kollidon®CL, in particular having a molecular weight in excess of 1 000 000, more particularly having a particle size distribution of less than 400 microns or less than 74 microns, or reactive additives (effervescent mixtures) that effect rapid disintegration of the tablet in the presence of water, for example so-called